Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tavapadon
- Development stage
- Approved
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Tavapadon** is an orally administered, non-ergot, selective dopamine D1/D5 receptor partial agonist developed for Parkinson's disease. It was originally discovered by Pfizer as PF-06649751, advanced by Cerevel as CVL-751, and acquired by AbbVie. In the United States, it was approved in September 2026 as **Juvmo** tablets for treatment of Parkinson's disease in adults, including use with or without levodopa therapy. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220415Orig1s000ltr.pdf))
- Brand names
- Juvmo
- Other names
- tavapadon
02
Targets
DRD1 (Dopamine D1 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on tavapadon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tavapadon.